Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary

Molecular Human Reproduction

Volumn 9, Issue 10, 2003, Pages 569-575

  Okamoto, Tomomitsu ^a   Niu, Rong ^b   Yamada, Satoru ^a  

^a CHUKYO HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clear cell carcinoma; MMP; Ovarian cancer; TIMP

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEIN PRECURSOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYST FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUCINOUS CARCINOMA; ORGAN CULTURE; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; WESTERN BLOTTING;

ADENOCARCINOMA, CLEAR CELL; BLOTTING, WESTERN; CULTURE MEDIA; CYSTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OVARIAN NEOPLASMS; PROTEIN PRECURSORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR CELLS, CULTURED;

FALLOPIA;

EID: 0141728381     PISSN: 13609947     EISSN: None     Source Type: Journal    
DOI: 10.1093/molehr/gag074     Document Type: Article

References (44)

1. Afzal, S., Lalani, E-N., Foulkes, W.D., Boyce, B., Tickle, S., Cardillo, M.R., Baker, T., Pignatelli, P. and Stamp, G.W.H. (1996) Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab. Invest., 74, 406-421.
2. Behbakht, K., Randall, T.C., Benjamin, I., Morgan, M.A., King, S. and Rubin, S.C. (1998) Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol., 70, 255-258.
3. Campo, E., Merino, M.J., Tavassoli, F.A., Charonis, A.S., Stetler-Stevenson, W.G. and Liotta, L.A. (1992) Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am. J. Surg. Pathol., 16, 500-507.
4. Chambers, A.F. and Matrisian, L.M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl Cancer Inst., 89, 1260-1270.
5. Corcoran, M.L. and Stetler-Stevenson, W.G. (1995) Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J. Biol. Chem., 270, 13453-13459.
6. Coussens, L.M., Fingleton, B. and Matrisian, L.M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science, 295, 2387-2392.
7. Davidson, B., Goldberg, I., Gotlieb, W.H., Kopolovic, J., Ben-Baruch, G., Nesland, J.M., Berner, A., Bryne, M. and Reich, R. (2000) High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metast., 17, 799-808.
8. Fishman, D.A., Bafetti, L.M., Banionis, S., Kearns, A.S., Chilukuri, K. and Stack, M.S. (1997) Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer, 80, 1457-1463.
9. Giannelli, G., Bergamini, C., Marinosci, F., Fransvea, E., Quaranta, M., Lupo, L., Schiraldi, O. and Antonaci, S. (2002) Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer, 97, 425-431.
10. Goff, B.A., Sainz de la Cuesta, R., Muntz, H.G., Fleischhacker, D., Ek, M., Rice, L.W., Nikrui, N., Tamini, H.K., Cain, J.M., Greer B.E. et al. (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol., 60, 412-417.
11. Goldberg, G.I., Strongin, A., Collier, I.E., Genrich, L.T. and Marmer, B.L. (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinase prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem., 267, 4583-4591.
12. Grignon, D.J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., Pontes, J.E., Crissman, J.C. and Fridman, R. (1996) High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res., 56, 1654-1659.
13. Herron, G.S., Banda, M.J., Clark, E.J., Gavrilovic, J. and Werb, Z. (1986) Secretion of metalloproteinases by stimulated capillary endothelial cell. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J. Biol. Chem., 261, 2814-2828.
14. Ho, E. S-C., Lai, C-R., Hsieh, Y-T., Chen, J-T., Lin, A-J., Hung, M-J. and Liu, F-S. (2001) p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol. Oncol., 80, 189-193.
15. Huang, L-W., Garrett, A.P., Bell, D.A., Welch, W.R., Berkowitz, R.S. and Mok, S.C. (2000) Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase- 1 protein and mRNA in epithelial ovarian tumors. Gvnecol. Oncol., 77, 369-376.
16. Jenison, E.L., Montag, A.G., Griffiths, C.T., Welch, W.R., Lavin, P.T., Greer, J. and Knapp, R.C. (1989) Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol. Oncol., 32, 65-71.
17. Kennedy, A.W., Biscotti, C.V., Hart, W.R. and Webster, K.D. (1989) Ovarian clear cell adenocarcinoma. Gynecol. Oncol., 32, 342-349.
18. Kugler, A., Hemmerlein, B., Thelen, P., Kallerhoff, M., Radzun, H.J. and Ringert, R.H. (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J. Urol., 160, 1914-1918.
19. Lein, M., Jung, K., Laube, C., Hübner, T., Winkelmann, B., Stephan, C., Hauptmann, S., Rudolph, B., Schnorr, D. and Loening, S. (2000) Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int. J. Cancer, 85, 801-804.
20. Lengyel, E., Schmalfeldt, B., Konik, E., Späthe, K., Härting, K., Fenn, A., Berger, U., Fridman, R., Schmitt, M., Prechtel, D. et al. (2001) Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol. Oncol., 82, 291-298.
21. Liotta, L.A., Rao, C.N. and Wewer, U.M. (1986) Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem., 55, 1037-1058.
22. Mignatti, P. and Rifkin, D.B. (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73, 161-195.
23. Miyake, H., Hara, I., Gohji, K., Yamanaka, K., Hara, S., Arakawa, S., Nakajima, M. and Kamidono, S. (1999) Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin. Cancer Res., 5, 2824-2829.
24. Naylor, M.S., Stamp, G.W., Davies, B.D. and Balkwill, F.R. (1994) Expression and activity of MMPs and their regulators in ovarian cancer. Int. J. Cancer, 58, 50-56.
25. Nictolis, M.D., Garbisa, S., Lucarini, G., Goteri, G., Masiero, L., Ciavattini, A., Garzetti, G.G., Stetler-Stevenson, W.G., Fabris, G., Biagini, G. et al. (1996) 72-kilodalton type IV collagenase, Type IV collagen, and Ki 67 antigen in serous tumors of the ovary: a clinicopathologic, immunohistochemical, and serological study. Int. J. Gynecol. Pathol., 15, 102-109.
26. Nuovo, G.J., Macconnell, P.B., Simsir, A., Valea, F. and French, D.L. (1995) Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res., 55, 267-272.
27. Ohkawa, K., Amasaki, H., Terashima, Y., Aizawa, S. and Ishikawa, E. (1977) Clear cell carcinoma of the ovary. Cancer, 40, 3019-3029.
28. Okamoto, T., Niu, R., Yamada, S. and Osawa, M. (2002) Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. Mol. Hum. Reprod., 8, 392-398.
29. Omura, G.A., Brady, M.F., Homesley, H.D., Yordan, E., Major, F.J., Buchsbaum, H.J. and Park, R.C. (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J. Clin. Oncol., 9, 1138-1150.
30. Ree, A.H., Flørenes, V.A., Berg, J.P., Mælandsmo, G.M., Nesland, J.M. and Fodstad, Ø. (1997) High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res., 3, 1623-1628.
31. Remacle, A., McCarthy, K., Nöel, A., Maguire, T., McDermott, E., O'Higgins, N., Foidart, J.M. and Duffy, M.J. (2000) High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int. J. Cancer, 89, 118-121.
32. Saika, S., Kawashima, Y., Okada, Y., Tanaka, S., Yamanaka, O., Ohnishi, Y. and Ooshima, A. (1998) Recombinant TIMP-1 and -2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelium in situ. Curr. Eye Res., 17, 47-52.
33. Sancho-Torres, I., Mesonero, C., Watelet, J-L.M., Gibbon, D. and Rodríguez-Rodríguez, L. (2000) Clear cell carcinoma of the ovary: characterization of its CD44 isoform repertoire. Gynecol. Oncol., 79, 187-195.
34. Shimizu, M., Nikaido, T., Toki, T., Shiozawa, T. and Fujii, S. (1999) Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer, 85, 669-677.
35. Simpson, K.S., Byers, M.J. and Curry, Jr, T.E. (2001) Spatiotemporal messenger ribonucleic acid expression of ovarian tissue inhibitors of metalloproteinases throughout the rat estrous cycle. Endocrinology, 142, 2058-2069.
36. Stetler-Stevenson, W.G., Krutzsch, H.C. and Liotta, L.A. (1989) Tissue inhibitor of metalloproteinase-2 (TIMP-2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem., 264, 17374-17378.
37. Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I. and Taguchi, K. (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer, 88, 2584-2589.
38. Udagawa, A., Okamoto, T., Nomura, S., Matsuo, K., Suzuki, H. and Mizutani, S. (1998) Human chorionic gonadotropin β-core fragment is present in the human placenta. Mol. Cell. Endocrinol., 139, 171-178.
39. Ueki, M. (2001) Report of gynecologic cancer in Japan. Acta Obstet. Gynecol. Jpn., 53, 1038-1048.
40. Valente, P., Fassina, G., Melchiori, A., Masiello, L., Cilli, M., Vacca, A., Onisto, M., Santi, L., Stetler-Stevenson, W.G. and Albini, A. (1998) TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer, 75, 246-253.
41. Wu, X., Haili, L., Kang, L., Li, L., Wang, W. and Shan, B. (2002) Activated matrix metalloproteinase-2-a potential marker of prognosis for epithelial ovarian cancer. Gynecol. Oncol., 84, 126-134.
42. Yamashita, K., Suzuki, M., Iwata, H., Koike, T., Hamaguchi, M., Shinagawa, A., Noguchi, T. and Hayakawa, T. (1996) Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett., 396, 103-107.
43. Yoonessi, M., Weldon, D., Satchidand, S.K. and Crickard, K. (1984) Clear cell ovarian adenocarcinoma. J. Surg. Oncol., 27, 289-297.
44. Yoshizaki, T., Maruyama, Y., Sato, H. and Furukawa, M. (2001) Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int. J. Cancer, 95, 44-50.